Flecainide is a narrow therapeutic index drug that requires careful patient selection and monitoring to avoid proarrhythmic effects.
There is much evidence for flecainide to be considered an NTID based on both preclinical and clinical data. A clear understanding of the potential of proarrhythmic effects or lack of efficacy, careful patient selection and regular monitoring are essential for the safe and rational administration of flecainide.
No takes yet. Share an insight, caveat, or question.
Tamargo et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: